{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:18:36Z","timestamp":1791512316521,"version":"4.3.4"},"reference-count":79,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:00:00Z","timestamp":1628294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Islatravir (MK-8591) is a nucleoside reverse transcriptase translocation inhibitor in development for the treatment and prevention of HIV-1. The potential for islatravir to interact with commonly co-prescribed medications was studied in vitro. Elimination of islatravir is expected to be balanced between adenosine deaminase\u2013mediated metabolism and renal excretion. Islatravir did not inhibit uridine diphosphate glucuronosyltransferase 1A1 or cytochrome p450 (CYP) enzymes CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4, nor did it induce CYP1A2, 2B6, or 3A4. Islatravir did not inhibit hepatic transporters organic anion transporting polypeptide (OATP) 1B1, OATP1B3, organic cation transporter (OCT) 1, bile salt export pump (BSEP), multidrug resistance-associated protein (MRP) 2, MRP3, or MRP4. Islatravir was neither a substrate nor a significant inhibitor of renal transporters organic anion transporter (OAT) 1, OAT3, OCT2, multidrug and toxin extrusion protein (MATE) 1, or MATE2K. Islatravir did not significantly inhibit P-glycoprotein and breast cancer resistance protein (BCRP); however, it was a substrate of BCRP, which is not expected to be of clinical significance. These findings suggest islatravir is unlikely to be the victim or perpetrator of drug-drug interactions with commonly co-prescribed medications, including statins, diuretics, anti-diabetic drugs, proton pump inhibitors, anticoagulants, benzodiazepines, and selective serotonin reuptake inhibitors.<\/jats:p>","DOI":"10.3390\/v13081566","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T21:35:40Z","timestamp":1628458540000},"page":"1566","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters"],"prefix":"10.3390","volume":"13","author":[{"given":"Kelly","family":"Bleasby","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ 07033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Houle","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ 07033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hafey","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ 07033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihong","family":"Lin","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ 07033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Guo","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ 07033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Lu","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ 07033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa I.","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ 07033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Fillgrove","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ 07033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Antiretroviral Therapy Cohort Collaboration (2008). Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet, 372, 293\u2013299.","DOI":"10.1016\/S0140-6736(08)61113-7"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e207954","DOI":"10.1001\/jamanetworkopen.2020.7954","article-title":"Comparison of Overall and Comorbidity-Free Life Expectancy between Insured Adults with and without HIV Infection, 2000\u20132016","volume":"3","author":"Marcus","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_3","unstructured":"UNAIDS (2021, July 22). UNAIDS Fact Sheet\u2014Global AIDS Update 2019. Available online: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_FactSheet_en.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/aje\/kws321","article-title":"Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984\u20132008","volume":"177","author":"Wada","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/jama.2019.19775","article-title":"Comorbidities in Persons with HIV: The Lingering Challenge","volume":"323","author":"Lerner","year":"2019","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1473-3099(15)00056-0","article-title":"Future challenges for clinical care of an ageing population infected with HIV: A modelling study","volume":"15","author":"Smit","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1097\/QAD.0000000000001215","article-title":"Chronic health conditions in Medicare beneficiaries 65 years old, and older with HIV infection","volume":"30","author":"Friedman","year":"2016","journal-title":"AIDS"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/cid\/cir627","article-title":"Premature age-related comorbidities among HIV-infected persons compared with the general population","volume":"53","author":"Guaraldi","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e25449","DOI":"10.1002\/jia2.25449","article-title":"The challenge of HIV treatment in an era of polypharmacy","volume":"23","author":"Back","year":"2020","journal-title":"J. Int. AIDS Soc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijid.2017.11.010","article-title":"Understanding mechanisms to promote successful aging in persons living with HIV","volume":"66","author":"Escota","year":"2018","journal-title":"Int. J. Infect. Dis."},{"key":"ref_11","first-page":"1525","article-title":"Comorbidities among US patients with prevalent HIV infection-a trend analysis","volume":"216","author":"Gallant","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/jgs.12695","article-title":"Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection","volume":"62","author":"Greene","year":"2014","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/cpt.1435","article-title":"Clinical studies on drug-drug interactions involving metabolism and transport: Methodology, pitfalls, and interpretation","volume":"105","author":"Tornio","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_14","unstructured":"European Medicines Agency (2021, July 22). Guideline on the Investigation of Drug Interactions. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf."},{"key":"ref_15","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research (2021, July 22). Clinical Drug Interaction Studies\u2014Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions."},{"key":"ref_16","unstructured":"(2021, July 22). PMDA Ministry of Labor and Welfare Guideline on Drug Interaction for Drug Development and Appropriate Provision of Information, Notification No.0723-4, Pharmaceutical Evaluation Division, Pharmaceuticals Safety and Environmental Health Bureau, Japan. Available online: https:\/\/www.pmda.go.jp\/files\/000228122.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/COH.0000000000000599","article-title":"Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1","volume":"15","author":"Markowitz","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/COH.0000000000000467","article-title":"4\u2032-Ethynyl-2-fluoro-2\u2032-deoxyadenosine, MK-8591: A novel HIV-1 reverse transcriptase translocation inhibitor","volume":"13","author":"Markowitz","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1016\/j.biocel.2008.04.007","article-title":"2\u2032-deoxy-4\u2032-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants","volume":"40","author":"Kawamoto","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"24533","DOI":"10.1074\/jbc.M114.562694","article-title":"4\u2032-Ethynyl-2-fluoro-2\u2032-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms","volume":"289","author":"Michailidis","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9274","DOI":"10.1073\/pnas.1605223113","article-title":"Structural basis of HIV inhibition by translocation-defective RT inhibitor 4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine (EFdA)","volume":"113","author":"Salie","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","unstructured":"DHHS (2021, July 22). Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services, Available online: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf."},{"key":"ref_23","unstructured":"Grobler, J., Lai, M.T., Barrett, S.E., Gindy, M., Fillgrove, K., Ankrom, W., Sandra, W., Friedman, E., Iwamoto, M., and Hazuda, D.J. (2016, January 22\u201325). Long-acting oral and parenteral dosing of MK-8591 for HIV treatment or prophylaxis. Proceedings of the Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, USA."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"35681","DOI":"10.1074\/jbc.M109.036616","article-title":"Mechanism of inhibition of HIV-1 reverse transcriptase by 4\u2032-Ethynyl-2-fluoro-2\u2032-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor","volume":"284","author":"Michailidis","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1128\/AAC.05036-14","article-title":"Oral administration of the nucleoside EFdA (4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque","volume":"59","author":"Stoddart","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1016\/S2352-3018(19)30372-8","article-title":"Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: An open-label, phase 1b, consecutive-panel trial","volume":"7","author":"Schurmann","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_27","unstructured":"Matthews, R.P., Jackson Rudd, D., Levine, V., Zhang, S., Sterling, L., Grobler, J.A., Vargo, R., Stoch, S.A., and Iwamoto, M. (2018, January 4\u20137). Multiple daily doses of MK-8591 as low as 0.25 mg are expected to suppress HIV. Proceedings of the Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, USA."},{"key":"ref_28","unstructured":"(2021, July 22). Clinicaltrials.gov. Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016) (NCT04003103), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04003103."},{"key":"ref_29","unstructured":"Hillier, S., Bekker, L.G., Badal-Faesen, S., Hendrix, C.W., Riddler, S.A., Rasmussen, S., Schwartz, H., Nair, G., Lombaard, J.H., and Caraco, Y. (2021, January 27\u201328). Trial design, enrollment status, demographics, and pharmacokinetic (PK) data from a blinded interim analysis from a phase 2a trial of islatravir once monthly (QM) for HIV pre-exposure prophylaxis (PrEP). Proceedings of the Conference on HIV Research for Prevention (HIVR4P), Virtual."},{"key":"ref_30","unstructured":"US Food and Drug Administration (2021, July 22). Drug Development and Drug Interactions: Table of Substrates, Inhbitors and Inducers, Available online: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table2-1."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","article-title":"Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)","volume":"21","author":"Hodges","year":"2011","journal-title":"Pharm. Genom."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport--an update","volume":"17","author":"Mao","year":"2015","journal-title":"AAPS J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-pharmtox-011613-140021","article-title":"Role of hepatic efflux transporters in regulating systemic and hepatocyte exposure to xenobiotics","volume":"54","author":"Pfeifer","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"The National Lipid Association\u2019s Safety Task F. A clinician\u2019s guide to statin drug-drug interactions","volume":"8","author":"Kellick","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.79","article-title":"ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin","volume":"86","author":"Keskitalo","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/clpt.2012.163","article-title":"Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: It\u2019s not just about OATP1B1","volume":"92","author":"Elsby","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1124\/dmd.113.051722","article-title":"Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions","volume":"41","author":"Shirasaka","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s13181-015-0465-0","article-title":"A review of the toxicity of HIV medications II: Interactions with drugs and complementary and alternative medicine products","volume":"11","author":"Stolbach","year":"2015","journal-title":"J. Med. Toxicol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0009-9236(97)90116-8","article-title":"Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin","volume":"62","author":"Bottiger","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/2042018816638050","article-title":"Clinically and pharmacologically relevant interactions of antidiabetic drugs","volume":"7","author":"May","year":"2016","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s40262-020-00907-w","article-title":"Validation of a drug transporter probe cocktail using the prototypical inhibitors rifampin, probenecid, verapamil, and cimetidine","volume":"59","author":"Wiebe","year":"2020","journal-title":"Clin. Pharm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin. Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1124\/dmd.109.028605","article-title":"Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes","volume":"37","author":"Moody","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"ref_44","first-page":"73","article-title":"The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268)","volume":"26","author":"Coffman","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"ref_45","first-page":"52","article-title":"Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7","volume":"45","author":"Cheng","year":"1998","journal-title":"Toxicol. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/j.bja.2018.12.007","article-title":"High-dose naloxone, an experimental tool uncovering latent sensitisation: Pharmacokinetics in humans","volume":"123","author":"Papathanasiou","year":"2019","journal-title":"Br. J. Anaesth."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40262-014-0230-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of clopidogrel","volume":"54","author":"Jiang","year":"2015","journal-title":"Clin. Pharm."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4103\/0253-7613.77360","article-title":"Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence","volume":"43","author":"Mistry","year":"2011","journal-title":"Indian J. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J. Am. Coll Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00004714-199806000-00015","article-title":"Alprazolam is another substrate for human cytochrome P450-3A isoforms","volume":"18","author":"Venkatakrishnan","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","article-title":"Inhibition and induction of CYP enzymes in humans: An update","volume":"94","author":"Hakkola","year":"2020","journal-title":"Arch. Toxicol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00004850-199603001-00002","article-title":"Pharmacology and pharmacokinetics of citalopram and other SSRIs","volume":"11","author":"Baumann","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_53","first-page":"927","article-title":"Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes","volume":"280","author":"Kobayashi","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1080\/00498254.2018.1451667","article-title":"Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans","volume":"49","author":"Sanchez","year":"2019","journal-title":"Xenobiotica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e02492-18","DOI":"10.1128\/AAC.02492-18","article-title":"In vitro evaluation of the drug interaction potential of doravirine","volume":"63","author":"Bleasby","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1124\/dmd.116.071076","article-title":"Evaluation of CYP2B6 induction and prediction of clinical drug-drug interactions: Considerations from the IQ Consortium Induction Working Group-an industry perspective","volume":"44","author":"Fahmi","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1124\/dmd.112.049668","article-title":"In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters","volume":"41","author":"Chu","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1128\/AAC.02049-13","article-title":"Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: An in vitro evaluation","volume":"58","author":"Rizk","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1124\/jpet.106.116517","article-title":"Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein","volume":"321","author":"Chu","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_60","unstructured":"(2021, July 22). The Human Protein Atlas. ADA. Available online: https:\/\/www.proteinatlas.org\/ENSG00000196839-ADA\/tissue."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1128\/AAC.01703-13","article-title":"Effects of substitutions at the 4\u2032 and 2 positions on the bioactivity of 4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine","volume":"57","author":"Kirby","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1124\/dmd.30.12.1497","article-title":"The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties","volume":"30","author":"Austin","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2710.1998.00086.x","article-title":"Clinically important pharmacokinetic drug-drug interactions: Role of cytochrome P450 enzymes","volume":"23","author":"Tanaka","year":"1998","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2147\/NDT.S157708","article-title":"Drug-drug interactions involving antidepressants: Focus on desvenlafaxine","volume":"14","author":"Low","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1521-0391.2009.00005.x","article-title":"Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review","volume":"19","author":"Sullivan","year":"2010","journal-title":"Am. J. Addict."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10072-015-2407-7","article-title":"Comparison of VerifyNow P2Y12 and thrombelastography for assessing clopidogrel response in stroke patients in China","volume":"37","author":"Lv","year":"2016","journal-title":"Neurol. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2174\/092986708785132870","article-title":"Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development","volume":"15","author":"Zhou","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/cpt.1222","article-title":"Can bile salt export pump inhibition testing in drug discovery and development reduce liver injury risk? an international transporter consortium perspective","volume":"104","author":"Kenna","year":"2018","journal-title":"Clin. Pharm. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1002\/jcph.735","article-title":"Renal transporter-mediated drug-drug interactions: Are they clinically relevant?","volume":"56","author":"Lepist","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","article-title":"Tenofovir disoproxil fumarate: Clinical pharmacology and pharmacokinetics","volume":"43","author":"Kearney","year":"2004","journal-title":"Clin. Pharm."},{"key":"ref_72","first-page":"354908","article-title":"Tenofovir nephrotoxicity: 2011 update","volume":"2011","author":"Sanz","year":"2011","journal-title":"AIDS Res. Treat."},{"key":"ref_73","unstructured":"Jackson Rudd, D., Cao, Y., Vaddady, P., Grobler, J.A., Asante-Appiah, E., Diamond, T., Klopfer, S., Grandhi, A., Hwang, C., and Vargo, R. (2020, January 8\u201311). Modeling-Supported Islatravir Dose Selection for Phase 3. Proceedings of the Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, USA."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Matthews, R., Ankrom, W., Friedman, E., Jackson Rudd, D., Liu, Y., Mogg, R., Panebianco, D., De Lepeleire, I., Petkova, M., and Grobler, J. (2021). Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIV. Clin. Trans. Sci., in press.","DOI":"10.1111\/cts.13048"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Matthews, R., Jackson Rudd, D., Fillgrove, K., Zhang, S., Tomek, C., Stoch, S.A., and Iwamoto, M. (2021). A phase 1 study to evaluate the drug interaction between islatravir (MK-8591) and doravirine in adults without HIV. Clin. Drug Investig., in press.","DOI":"10.1007\/s40261-021-01046-1"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","article-title":"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor","volume":"41","author":"Reese","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Ankrom, W., Jonathan, D., Jackson Rudd, D., Zhang, S., Gravesande, K., Matthews, R., Brimhall, D., Stoch, S.A., and Iwamoto, M. (2018, January 3\u20137). MK-8591 Does Not Alter the Pharmacokinetics of the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol. Proceedings of the IDWeek 2018, San Francisco, CA, USA.","DOI":"10.1093\/ofid\/ofy210.559"},{"key":"ref_78","unstructured":"Pfizer Inc. (2017). ALESSE\u00ae [Product Information], Pfizer Canada Inc."},{"key":"ref_79","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research (2021, July 22). In Vitro Metabolism- and Transporter-Mediated Drug-Drug Interaction Studies Guidance for Industry, Available online: https:\/\/www.fda.gov\/media\/108130\/download."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/8\/1566\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:42:19Z","timestamp":1760164939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/8\/1566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,7]]},"references-count":79,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["v13081566"],"URL":"https:\/\/doi.org\/10.3390\/v13081566","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,7]]}}}